Candriam Luxembourg S.C.A. Has $2.27 Million Stake in Global Blood Therapeutics, Inc. (GBT)

Candriam Luxembourg S.C.A. increased its position in Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 7.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 83,000 shares of the company’s stock after buying an additional 6,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Global Blood Therapeutics were worth $2,270,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of GBT. FMR LLC increased its position in shares of Global Blood Therapeutics by 2.9% in the first quarter. FMR LLC now owns 5,759,471 shares of the company’s stock worth $212,236,000 after buying an additional 162,004 shares during the period. Perceptive Advisors LLC increased its position in shares of Global Blood Therapeutics by 23.3% in the first quarter. Perceptive Advisors LLC now owns 3,858,978 shares of the company’s stock worth $142,203,000 after buying an additional 730,000 shares during the period. BlackRock Inc. increased its position in shares of Global Blood Therapeutics by 4,675.5% in the first quarter. BlackRock Inc. now owns 2,618,847 shares of the company’s stock worth $96,503,000 after buying an additional 2,564,008 shares during the period. Vanguard Group Inc. increased its position in shares of Global Blood Therapeutics by 40.1% in the first quarter. Vanguard Group Inc. now owns 2,535,980 shares of the company’s stock worth $93,451,000 after buying an additional 726,366 shares during the period. Finally, Wellington Management Group LLP increased its position in shares of Global Blood Therapeutics by 10.8% in the first quarter. Wellington Management Group LLP now owns 2,321,123 shares of the company’s stock worth $85,534,000 after buying an additional 225,994 shares during the period. Institutional investors own 72.29% of the company’s stock.

Shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) opened at 27.00 on Friday. The company’s market capitalization is $1.18 billion. Global Blood Therapeutics, Inc. has a one year low of $13.35 and a one year high of $41.15. The firm has a 50-day moving average price of $28.16 and a 200-day moving average price of $28.64.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings data on Monday, August 7th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.06. During the same period in the previous year, the firm posted ($0.58) earnings per share. Equities analysts forecast that Global Blood Therapeutics, Inc. will post ($2.48) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/2802305/candriam-luxembourg-s-c-a-has-2-27-million-stake-in-global-blood-therapeutics-inc-gbt.html.

GBT has been the subject of a number of analyst reports. BidaskClub downgraded Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, June 20th. Morgan Stanley restated an “overweight” rating on shares of Global Blood Therapeutics in a research report on Tuesday, July 11th. Janney Montgomery Scott initiated coverage on Global Blood Therapeutics in a research report on Monday, May 1st. They set a “buy” rating and a $37.00 price objective for the company. J P Morgan Chase & Co restated an “overweight” rating and set a $46.00 price objective (up from $44.00) on shares of Global Blood Therapeutics in a research report on Tuesday. Finally, Oppenheimer Holdings, Inc. initiated coverage on Global Blood Therapeutics in a research report on Friday, August 4th. They set an “outperform” rating and a $53.00 price objective for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $50.75.

In other Global Blood Therapeutics news, Director Deval L. Patrick sold 27,053 shares of the stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $29.69, for a total value of $803,203.57. Following the completion of the sale, the director now owns 12,053 shares in the company, valued at approximately $357,853.57. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Jung Choi sold 3,000 shares of the stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the sale, the insider now owns 143,255 shares of the company’s stock, valued at approximately $4,297,650. The disclosure for this sale can be found here. Company insiders own 5.30% of the company’s stock.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.